SAN DIEGO — All 38 patients with heavily pretreated multiple myeloma responded to an investigational chimeric antigen receptor T-cell therapy, results of a phase 1 study presented at ASH Annual Meeting and Exhibition showed.
The CAR-T product, now known as anitocabtagene autoleucel — also known as anito-cel — showed low levels of key toxicities related to the use of CAR-T, including cytokine release syndrome and neurotoxicity, according to study investigators.
“We are seeing durable responses using this therapy,” Matthew J. Frigault, MD, administrative director of
